PROM1 and colon carcinoma: Additionally, as CD133 has been widely studied in colon adenocarcinoma cell lines [28–30], including the HCT116 line, we introduced CD133 knockout in the colon carcinoma cell line HCT116 with the CRISPR/Cas9 system.